


La molécule du mois - What molecule am I ?



Baricitinib

Baricitinib is an orally-administered JAK inhibitor for rheumatoid arthritis (RA) developed by Eli Lilly and Incyte Corporation. JAK family members play key role in a number of inflammatory and autoimmune diseases. Another JAK inhibitors are currently on the market but also in various stages of clinical development for the treatment of hematologic cancers, psoriasis or for reducing transplant rejection.

Baricitinib was approved in the EU in February 2017 (Olmiant®) as the first Janus kinase (JAK) inhibitor for the treatment of **rheumatoid arthritis**.

Contribution : David MONTOIR & Abdallah HAMZE June 2017